☰

Christopher Szeto, Ph.D. - Publications

Affiliations: 
Biomolecular Engineering and Bioinformatics University of California, Santa Cruz, Santa Cruz, CA, United States 
Tree Info Similar researchers PubMed Report error

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Fasching PA, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, van Mackelenbergh M, et al. Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37014668 DOI: 10.1158/1078-0432.CCR-22-2213  0.659
2022 Burton KA, Mahen E, Konnick EQ, Blau S, Dorschner MO, Ramirez AB, Schmechel SC, Song C, Parulkar R, Parker S, Senecal FM, Pritchard CC, Mecham BH, Szeto C, Spilman P, et al. Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer. Jco Precision Oncology. 6: e2100280. PMID 35294224 DOI: 10.1200/PO.21.00280  0.618
2020 Newton Y, Sedgewick AJ, Cisneros L, Golovato J, Johnson M, Szeto CW, Rabizadeh S, Sanborn JZ, Benz SC, Vaske C. Large scale, robust, and accurate whole transcriptome profiling from clinical formalin-fixed paraffin-embedded samples. Scientific Reports. 10: 17597. PMID 33077815 DOI: 10.1038/s41598-020-74483-1  0.722
2020 Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R. Transcriptomic silencing as a potential mechanism of treatment resistance. Jci Insight. 5. PMID 32493840 DOI: 10.1172/Jci.Insight.134824  0.76
2020 Jaber MI, Song B, Taylor C, Vaske CJ, Benz SC, Rabizadeh S, Soon-Shiong P, Szeto CW. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival. Breast Cancer Research : Bcr. 22: 12. PMID 31992350 DOI: 10.1186/S13058-020-1248-3  0.634
2020 Reddy SK, Seery TE, Szeto C. Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients. Journal of Clinical Oncology. 38: 20-20. DOI: 10.1200/Jco.2020.38.4_Suppl.20  0.44
2020 Szeto C, Gounder MM, Parulkar R, Nguyen A, Rabizadeh S, Reddy SK. High correlation between TMB, expressed TMB, and neoantigen load using tumor: Normal whole exome DNA and matched whole transcriptome RNA sequencing. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15238  0.417
2020 Benz SC, Beziaeva L, Jaber M, Rabizadeh S, Szeto C. Highly accurate automated tissue classification using deep learning on digital pathology images: A novel tool for resolving conflicts in diagnosis. Journal of Clinical Oncology. 38: 3578-3578. DOI: 10.1200/Jco.2020.38.15_Suppl.3578  0.643
2020 Adashek JJ, Szeto C, Sanborn JZ, Reddy SK, Toor AA, Danielides S, Smith S, Grossman SR, Clevenger CV, Faber A, Ferreira-Gonzalez A, Boikos SA. Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities. Journal of Clinical Oncology. 38: 3576-3576. DOI: 10.1200/Jco.2020.38.15_Suppl.3576  0.465
2020 Szeto C, Veerapaneni S, Parulkar R, Reddy SK, Rabizadeh S, Benz SC. Effect of chemokine signaling signatures on resolving discrepancy between TMB and checkpoint expression. Journal of Clinical Oncology. 38: 3131-3131. DOI: 10.1200/Jco.2020.38.15_Suppl.3131  0.683
2020 Fasching PA, Denkert C, Benz S, Weber KE, Szeto C, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, Mackelenbergh Mv, Rabizadeh S, et al. Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd5-08  0.703
2020 Szeto C, Denkert C, Fasching PA, Benz S, Weber KE, Budczies J, Schneeweiss A, Stickeler E, Schmatloch S, Jackisch C, Karn T, Sinn HP, Warm M, Mackelenbergh Mv, Rabizadeh S, et al. Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-10-04  0.661
2020 Williams T, Schneeweiss A, Jackisch C, Shen C, Weber K, Fasching P, Denkert C, Furlanetto J, Heinmoller E, Schmatloch S, Karn T, Szeto C, Mackelenbergh Mv, Nekljudova V, Stickeler E, et al. Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P1-10-01  0.388
2019 Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos AP, Rugge M, Munari G, Nguyen A, Szeto C, Zagonel V, Lonardi S, Fassan M. Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. Journal For Immunotherapy of Cancer. 7: 297. PMID 31703605 DOI: 10.1186/S40425-019-0788-5  0.421
2019 Wnuk K, Sudol J, Givechian KB, Soon-Shiong P, Rabizadeh S, Szeto C, Vaske C. Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity. Iscience. 20: 119-136. PMID 31563852 DOI: 10.1016/J.Isci.2019.09.018  0.452
2019 Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Rumfield CS, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. Oncoimmunology. 8: e1532764. PMID 30713787 DOI: 10.1080/2162402X.2018.1532764  0.311
2019 Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, et al. Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European Journal of Cancer (Oxford, England : 1990). 107: 164-174. PMID 30579113 DOI: 10.1016/J.Ejca.2018.11.016  0.351
2019 Adashek JJ, Kato S, Parulkar R, Szeto C, Reddy SK, Kurzrock R. RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics. Journal of Clinical Oncology. 37: 583-583. DOI: 10.1200/Jco.2019.37.7_Suppl.583  0.448
2019 Pal SK, Szeto C, Reddy SK, Nussenzveig R, Lam RY, Scholz MC, Agarwal N. Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 286-286. DOI: 10.1200/Jco.2019.37.7_Suppl.286  0.346
2019 Szeto C, Garner C, Kazmierczak K, Vaske CJ, Benz SC, Reddy SK. CMS subtypes characterized by high TMB shows immunosuppressive microenvironment that implies resistance to immunotherapy. Journal of Clinical Oncology. 37: 610-610. DOI: 10.1200/Jco.2019.37.4_Suppl.610  0.686
2019 Szeto C, Kazmierczak K, Chambers A, Kim YJ, Nguyen A, Tan IB, Benz SC, Vaske CJ. Comprehensive -omic analysis of 152 CRC patients allows greater subclassification than CMS or sidedness alone. Journal of Clinical Oncology. 37: 601-601. DOI: 10.1200/Jco.2019.37.4_Suppl.601  0.695
2019 Szeto C, Veerapaneni S, Kazmierczak K, Benz SC, Reddy SK, Yan D. Comprehensive profiling of immune landscape in gastrointestinal (GI) and head and neck (HN) cancers via computational deconvolution. Journal of Clinical Oncology. 37: 579-579. DOI: 10.1200/Jco.2019.37.4_Suppl.579  0.703
2019 Newton Y, Golovato J, Tan IB, Lam JYC, Yu G, Koo S, Chua C, Yeong JPS, Ping C, Skanderup A, Göke J, Johnson M, Rabizadeh S, Sanborn JZ, Benz SC, ... ... Szeto C, et al. Genomic and immune infiltration differences between MSI and MSS GI tumors. Journal of Clinical Oncology. 37: 528-528. DOI: 10.1200/Jco.2019.37.4_Suppl.528  0.779
2019 Vaske CJ, Garner C, Seery TE, Szeto C, Reddy SK. Clinical trial screening of CDKN2A genomic alterations in patients with pancreatic cancer and hepatobiliary cancers requires greater precision than somatic sequencing alone. Journal of Clinical Oncology. 37: 287-287. DOI: 10.1200/Jco.2019.37.4_Suppl.287  0.504
2019 Edenfield WJ, Merchant K, Martin JC, Drusbosky L, Elliott MH, Reddy SK, Szeto C, Cecchi F, Schammel C, Schammel DP, Grinstead RM, Chung KY. Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E12510  0.323
2019 Parulkar R, Nguyen A, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kato S, Kurzrock R, Szeto C. Evidence for selective silencing of MHC-binding neoepitopes to avoid immune surveillance. Journal of Clinical Oncology. 37: 2591-2591. DOI: 10.1200/Jco.2019.37.15_Suppl.2591  0.669
2019 Drusbosky L, Szeto C, Reddy SK, Ghotra M, Toor AA, Smith S, Faber A, Boikos SA. Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors. Journal of Clinical Oncology. 37: 1524-1524. DOI: 10.1200/Jco.2019.37.15_Suppl.1524  0.354
2019 Obeid E, Reddy S, Goldstein L, Daly M, Benz S, Hall M, Szeto C. Abstract P4-03-03: Germline potentially pathogenic variants in breast cancer intrinsic molecular subtypes are not associated with somatic TMB Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-03-03  0.456
2019 Gordon EM, Szeto C, Ravicz JR, Reddy S, Morse M, Chawla S, Hall F. Abstract 2556: Enhanced expression of human cyclin G1 (CCNG1) gene in metastatic cancer, a novel biomarker in development for CCNG1 inhibitor therapy Cancer Research. 79: 2556-2556. DOI: 10.1158/1538-7445.Am2019-2556  0.481
2019 Newton Y, Szeto C, Vaske C, Reddy L, Reddy S. Abstract 2533: The genomic and transcriptomic landscape of left versus right sided breast cancer in 410 cases Cancer Research. 79: 2533-2533. DOI: 10.1158/1538-7445.Am2019-2533  0.452
2018 Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, ... ... Szeto C, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nature Medicine. PMID 29808010 DOI: 10.1038/S41591-018-0022-X  0.41
2018 Tan IB, Nguyen A, Vaske CJ, Szeto C, Newton Y, Becht E, Yeong JPS, Benz SC, Thangaraju S, Lim B, Ho D, Lim KHT, Chua CWL, Mathew R, Tang CL, et al. RNA-Seq analyses of immune cell-type enrichments in 158 Asian colorectal cancers (CRCs). Journal of Clinical Oncology. 36: e15597-e15597. DOI: 10.1200/Jco.2018.36.15_Suppl.E15597  0.666
2018 Okamura R, Kato S, Parulkar R, Szeto C, Reddy S, Kurzrock R. Genomic landscape of diverse rare tumors: Next-generation sequencing of paired DNA and RNA analysis. Journal of Clinical Oncology. 36: 12114-12114. DOI: 10.1200/Jco.2018.36.15_Suppl.12114  0.41
2018 Pal SK, Vanderwalde AM, Szeto C, Benz SC, Sanborn JZ, Vaske CJ, Reddy SK, Hamid O. Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression. Journal of Clinical Oncology. 36: 12113-12113. DOI: 10.1200/Jco.2018.36.15_Suppl.12113  0.748
2018 Schwartz S, Cecchi F, Tian Y, Yau C, Szeto C, Rübner M, Erber R, Beckmann M, Hartmann A, Benz S, Hembrough T, Fasching P. Abstract P2-10-06: Identifying patients sensitive to anthracycline-containing therapy with quantitative proteomic and genomic profiling Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-10-06  0.497
2018 Szeto C, Benz S, Nguyen A, Rübner M, Wallwiener D, Tesch H, Hadji P, Fehm T, Janni W, Overkamp F, Lueftner D, Lux M, Wallwiener M, Beckmann M, Huebner H, et al. Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-07-20  0.466
2018 Parulkar R, Benz S, Vaske C, Radenbaugh A, Szeto C. Abstract 1182: Exploring longitudinal intra-tumor heterogeneity in cancer using whole genome sequencing and RNA rescue Tumor Biology. DOI: 10.1158/1538-7445.Am2018-1182  0.483
2017 Wnuk K, Sudol J, Rabizadeh S, Soon-Shiong P, Szeto C, Vaske C. Abstract 393: Predicting DNA accessibility in the pan-cancer tumor genome using RNA-Seq, WGS, and deep learning Cancer Research. 77: 393-393. DOI: 10.1158/1538-7445.Am2017-393  0.437
2012 Zhu J, Craft B, Swatloski T, Ellrott K, Goldman M, Wilks C, Ma S, Szeto C, Collisson E, Haussler D. Abstract 5087: UCSC Cancer Genomics Browser 2.0 Cancer Research. 72: 5087-5087. DOI: 10.1158/1538-7445.Am2012-5087  0.614
2011 Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ, Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D, Zhu J. The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Research. 39: D951-9. PMID 21059681 DOI: 10.1093/Nar/Gkq1113  0.783
2011 Zhu J, Sanborn JZ, Benz SC, Craft B, Szeto C, Kober KM, Goldman M, Meyer L, Vaske C, Collisson E, Stuart J, Haussler D. Abstract 4985: The UCSC Cancer Genomics Browser Cancer Research. 71: 4985-4985. DOI: 10.1158/1538-7445.Am2011-4985  0.751
2011 Ng S, Vaske C, Benz S, Durbin J, Szeto C, Heiser L, Wang N, Korkola J, Bayani N, Spellman P, Gray JW, Haussler D, Stuart J. Abstract 49: Constructing pathway based predictors of cancer clinical outcome Cancer Research. 71: 49-49. DOI: 10.1158/1538-7445.Am2011-49  0.622
2010 Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (Oxford, England). 26: i237-45. PMID 20529912 DOI: 10.1093/Bioinformatics/Btq182  0.752
2009 Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T. The UCSC Cancer Genomics Browser. Nature Methods. 6: 239-40. PMID 19333237 DOI: 10.1038/Nmeth0409-239  0.771
2009 Zhu J, Sanborn J, Wang T, Hsu F, Benz S, Szeto C, Esserman L, Haussler D. UCSC cancer genomics browser. Cancer Research. 69: 2022. DOI: 10.1158/0008-5472.Sabcs-2022  0.751
Show low-probability matches.